Molecular imaging of adrenal neoplasms

Journal of Surgical Oncology

Volumn 106, Issue 5, 2012, Pages 532-542

  Chen, Clara C ^a   Carrasquillo, Jorge A ^b,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

FDG; fluorodopa; MIBG; neuroblastoma; pheochromocytoma; somatostatin

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; 6 BETAIODOMETHYL NORCHOLESTEROL I 131; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE F 18; DOTANOC; DOTATATE; DOTATOC GA 68; FLUORODEOXYGLUCOSE F 18; FLUOROETIMODATE F 18; META HYDROXYEPHEDRINE C 11; METOMIDATE C 11; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SCINTIADREN; SELENOMETHYL NORCHOLESTEROL SE 75; UNCLASSIFIED DRUG;

ADRENAL CANCER; ADRENAL CORTEX CARCINOMA; BONE SCINTISCANNING; CANCER DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; METASTASIS; MOLECULAR IMAGING; NEUROBLASTOMA; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SOMATOSTATIN RECEPTOR SCINTIGRAPHY;

ADRENAL GLAND NEOPLASMS; ANIMALS; HUMANS; MOLECULAR IMAGING;

EID: 84866381503     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23162     Document Type: Review

References (116)

1. Wieland DM, Swanson DP, Brown LE, et al.: Imaging the adrenal-medulla with an 1-131-labeled antiadrenergic agent. J Nucl Med 1979; 20: 155-158. (Pubitemid 9129566)
2. Kolby L, Bernhardt P, Levin-Jakobsen AM, et al.: Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 2003; 89: 1383-1388. (Pubitemid 37368903)
3. Furuta N, Kiyota H, Yoshigoe F, et al.: Diagnosis of pheochromocytoma using [I-123]-compared with [I-131]-metaiodobenzylguanidine scintigraphy. Int J Urol 1999; 6: 119-124. (Pubitemid 30406825)
4. Hoyer D, Bell GI, Berelowitz M, et al.: Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16: 86-88.
5. Khan MU, Khan S, Ei-Refaie S, et al.: Clinical indications for Gallium-68 positron emission tomography imaging. Eur J Surg Oncol 2009; 35: 561-567.
6. Song YS, Lee WW, Chung JH, et al.: Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer 2008; 61: 54-60.
7. Delbeke D, Coleman RE, Guiberteau MJ, et al.: Procedure guideline for tumor imaging with F-18-FDG PET/CT 1.0. J Nucl Med 2006; 47: 885-895. (Pubitemid 46768453)
8. Jager PL, Chirakal R, Marriott CJ, et al.: 6-L-F-18- fluorodihydroxyphenylalanine PET in neuroendocrine tumors: Basic aspects and emerging clinical applications. J Nucl Med 2008; 49: 573-586. (Pubitemid 351520605)
9. Pacak K, Eisenhofer G, Carrasquillo JA, et al.: 6- F-18 fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 2001; 38: 6-8. (Pubitemid 34224762)
10. Eisenhofer G:, The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 2001; 91: 35-62. (Pubitemid 33055773)
11. Mann GN, Link JM, Pham P, et al.: [C-11]Metahydroxyephedrine and [F-18]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol 2006; 13: 187-197. (Pubitemid 43157413)
12. Rubello D, Bui C, Casara D, et al.: Functional scintigraphy of the adrenal gland. Eur J Endocrinol 2002; 147: 13-28. (Pubitemid 34814735)
13. Zettinig G, Mitterhauser M, Wadsak W, et al.: Positron emission tomography imaging of adrenal masses: F-18-fluorodeoxyglucose and the 11 beta-hydroxylase tracer C-11-metomidate. Eur J Nucl Med Mol Imaging 2004; 31: 1224-1230. (Pubitemid 39222485)
14. Bergstrom M, Juhlin C, Bonasera TA, et al.: PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med 2000; 41: 275-282. (Pubitemid 30091347)
15. Wadsak W, Mitterhauser M, Rendl G, et al.: [18F]FETO for adrenocortical PET imaging: A pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging 2006; 33: 669-672. (Pubitemid 43846757)
16. Hahner S, Stuermer A, Kreissl M, et al.: [123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J Clin Endocrinol Metab 2008; 93: 2358-2365. (Pubitemid 351831559)
17. Hahner S, Kreissl MC, Fassnacht M, et al.: [131I]Iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab 2012; 97: 914-922.
18. Gross MD, Djekidel M, Hay RV, et al.: Scintigraphic localization of adrenal tumors. Minerva Endocrinol 2009; 34: 171-184.
19. Maurea S, Klain M, Caraco C, et al.: Diagnostic accuracy of radionuclide imaging using I-131 nor-cholesterol or meta-iodobenzylguanidine in patients with hypersecreting or non-hypersecreting adrenal tumours. Nucl Med Commun 2002; 23: 951-960. (Pubitemid 35178295)
20. Fig LM, Gross MD, Shapiro B, et al.: Adrenal localization in the adrenocorticotropic hormone-independent Cushing syndrome. Ann Intern Med 1988; 109: 547-553.
21. Park JR, Stewart CF, London WB, et al.: A topotecan-containing induction regimen for treatment of high risk neuroblastoma. J Clin Oncol 2006; 24: 505s-505s.
22. Barzon L, Zucchetta P, Boscaro M, et al.: Scintigraphic patterns of adrenocortical carcinoma: Morpho-functional correlates. Eur J Endocrinol 2001; 145: 743-748. (Pubitemid 33133681)
23. Bagheri B, Maurer AH, Cone L, et al.: Characterization of the normal adrenal gland with F-18-FDG PET/CT. J Nucl Med 2004; 45: 1340-1343. (Pubitemid 47618533)
24. Song JH, Chaudhry FS, Mayo-Smith WW:, The incidental adrenal mass on CT: Prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy. Am J Roentgenol 2008; 190: 1163-1168. (Pubitemid 351684914)
25. Hammarstedt L, Muth A, Wangberg B, et al.: Adrenal lesion frequency: A prospective, cross-sectional CT study in a defined region, including systematic re-evaluation. Acta Radiol 2010; 51: 1149-1156.
26. Hedeland H, Ostberg G, Hokfelt B:, On the prevalence of adrenocortical adenomas in an autopsy material in relation to hypertension and diabetes. Acta Med Scand 1968; 184: 211-214.
27. Abrams HL, Spiro R, Goldstein N:, Metastases in carcinoma-analysis of 1000 autopsied cases. Cancer 1950; 3: 74-85.
28. Boland GWL, Dwamena BA, Sangwaiya MJ, et al.: Characterization of adrenal masses by using FDG PET: A systematic review and meta-analysis of diagnostic test performance. Radiology 2011; 259: 117-126.
29. Metser U, Miller E, Lerman H, et al.: F-18-FDG PET/CT in the evaluation of adrenal masses. J Nucl Med 2006; 47: 32-37. (Pubitemid 46768509)
30. Brady MJ, Thomas J, Wong TZ, et al.: Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: A proposal for an efficient Diagnostic algorithm. Radiology 2009; 250: 523-530.
31. Ozcan Kara P, Kara T, Gedik GK, et al.: The role of fluorodeoxyglucose- positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions. Nucl Med Commun 2011; 32: 106-112.
32. Perri M, Erba P, Volterrani D, et al.: Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis. Am J Roentgenol 2011; 197: 209-216.
33. Boland GWL, Blake MA, Holalkere NS, et al.: PET/CT for the characterization of adrenal masses in patients with cancer: Qualitative versus quantitative accuracy in 150 consecutive patients. Am J Roentgenol 2009; 192: 956-962.
34. Jana S, Zhang T, Milstein DM, et al.: FDG-PET and CT characterization of adrenal lesions in cancer patients. Eur J Nucl Med Mol Imaging 2006; 33: 29-35. (Pubitemid 41785306)
35. Han SJ, Kim TS, Jeon SW, et al.: Analysis of adrenal masses by F-18-FDG positron emission tomography scanning. Int J Clin Practice 2007; 61: 802-809.
36. Caoili EM, Korobkin M, Brown RKJ, et al.: Differentiating adrenal adenomas from nonadenomas using F-18-FDG PET/CT: Quantitative and qualitative evaluation. Acad Radiol 2007; 14: 468-475. (Pubitemid 46420545)
37. Gratz S, Kemke B, Kaiser W, et al.: Incidental non-secreting adrenal masses in cancer patients: Intra-individual comparison of (18)F- Fluorodeoxyglucose positron emission tomography/computed tomography with computed tomography and shift magnetic resonance imaging. J Int Med Res 2010; 38: 633-644.
38. Repko BM, Tulchinsky M:, Increased F-18 FDG uptake in resolving atraumatic bilateral adrenal hemorrhage (hematoma) on PET/CT. Clin Nucl Med 2008; 33: 651-653.
39. Tessonnier L, Sebag F, Palazzo FF, et al.: Does F-18-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours ? Eur J Nucl Med Mol Imaging 2008; 35: 2018-2025.
40. Nunes ML, Rault A, Teynie J, et al.: 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning. World J Surg 2010; 34: 1506-1510.
41. Groussin L, Bonardel G, Silvera S, et al.: (18)F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: A prospective study in 77 operated patients. J Clin Endocrinol Metab 2009; 94: 1713-1722.
42. Ansquer C, Scigliano S, Mirallie E, et al.: (18)F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: A prospective multicentre evaluation. Eur J Nucl Med Mol Imaging 2010; 37: 1669-1678.
43. Balasubramaniam S, Fojo T:, Practical considerations in the evaluation and management of adrenocortical cancer. Semin Oncol 2010; 37: 619-626.
44. Becherer A, Vierhapper H, Potzi C, et al.: FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm 2001; 16: 289-295. (Pubitemid 32938868)
45. Mackie GC, Shulkin BL, Ribeiro RC, et al.: Use of (18)F fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91: 2665-2671. (Pubitemid 44024634)
46. Leboulleux S, Dromain C, Bonniaud G, et al.: Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: A prospective comparison with computed tomography. J Clin Endocrinol Metab 2006; 91: 920-925. (Pubitemid 43357759)
47. Gust L, Taieb D, Beliard A, et al.: Preoperative 18F-FDG uptake is strongly correlated with malignancy, weiss score, and molecular markers of aggressiveness in adrenal cortical tumors. World J Surg 2012; 36: 1406-1410.
48. Leboulleux S, Deandreis D, Escourrou C, et al.: Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: Do not consider it as malignancy. Eur J Endocrinol 2011; 164: 89-94.
49. Minn H, Salonen A, Friberg J, et al.: Imaging of adrenal incidentalomas with PET using C-11-metomidate and F-18-FDG. J Nucl Med 2004; 45: 972-979. (Pubitemid 47611684)
50. Hennings J, Lindhe O, Bergstrom M, et al.: [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 2006; 91: 1410-1414.
51. Hennings J, Hellman P, Ahlstrom H, et al.: Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas. Eur J Radiol 2009; 69: 314-323.
52. Khan TS, Sundin A, Juhlin C, et al.: C-11-metomidate PET imaging of adrenocortical cancer. Eur J Nucl Med Mol Imaging 2003; 30: 403-410. (Pubitemid 36692866)
53. Mitterhauser M, Dobrozemsky G, Zettinig G, et al.: Imaging of adrenocortical metastases with [11C]metomidate. Eur J Nucl Med Mol Imaging 2006; 33: 974.
54. Timmers H, Chen CC, Carrasquillo JA, et al.: Comparison of (18)F-fluoro-L-DOPA, (18)F-fluoro-deoxyglucose, and (18)F-fluorodopamine PET and (123)I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2009; 94: 4757-4767.
55. Taieb D, Sebag F, Barlier A, et al.: F-18-FDG avidity of pheochromocytomas and paragangliomas: A new molecular imaging signature ? J Nucl Med 2009; 50: 711-717.
56. Gimenez-Roqueplo AP, Favier J, Rustin P, et al.: Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 2002; 87: 4771-4774. (Pubitemid 35247074)
57. Kaji P, Carrasquillo JA, Linehan WM, et al.: The role of 6- F-18 fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol 2007; 156: 483-487. (Pubitemid 46672650)
58. Wiseman GA, Pacak K, O'Dorisio MS, et al.: Usefulness of (123)I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: Results from a prospective multicenter trial. J Nucl Med 2009; 50: 1448-1454.
59. Jacobson AF, Deng HW, Lombard J, et al.: (123)I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: Results of a meta-analysis. J Clin Endocrinol Metab 2010; 95: 2596-2606.
60. Van Der Horst-Schrivers ANA, Jager PL, Boezen HM, et al.: Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas-Experience and meta-analysis. Anticancer Res 2006; 26: 1599-1604.
61. Bhatia KSS, Ismail MM, Sahdev A, et al.: I-123-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol 2008; 69: 181-188. (Pubitemid 352009037)
62. Timmers H, Kozupa A, Chen CC, et al.: Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 2007; 25: 2262-2269. (Pubitemid 46954653)
63. Fottner C, Helisch A, Anlauf M, et al.: 6-(18)F-fluoro-L- dihydroxyphenylalanine positron emission tomography is superior to (123)I-metaiodobenzyl-guanidine Scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: With vesicular monoamine transporter expression. J Clin Endocrinol Metab 2010; 95: 2800-2810.
64. Mozley PD, Kim CK, Mohsin J, et al.: The efficacy of iodine-123-MIBG as a screening-test for pheochromocytoma. J Nucl Med 1994; 35: 1138-1144.
65. Meyer-Rochow GY, Schembri GP, Benn DE, et al.: The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol 2010; 17: 392-400.
66. Ilias I, Chen CC, Carrasquillo JA, et al.: Comparison of 6-(18) F-fluorodopamine PET with (123)I-metaiodobenzylguanidine and (111)in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med 2008; 49: 1613-1619.
67. Franzius C, Hermann K, Weckesser M, et al.: Whole-body PET/CT with C-11-meta-hydroxyephedrine in tumors of the sympathetic nervous system: Feasibility study and comparison with I-123-MIBG SPECT/CT. J Nucl Med 2006; 47: 1635-1642. (Pubitemid 47545029)
68. Shulkin BL, Thompson NW, Shapiro B, et al.: Pheochromocytomas: Imaging with 2-[fluorine-18] fluoro-2-deoxy-D-glucose PET. Radiology 1999; 212: 35-41. (Pubitemid 29302508)
69. Hoegerle S, Nitzsche E, Altehoefer C, et al.: Pheochromocytomas: Detection with F-18 DOPA whole-body PET-Initial results. Radiology 2002; 222: 507-512. (Pubitemid 34106126)
70. Timmers H, Hadi M, Carrasquillo JA, et al.: The effects of carbidopa on uptake of 6-F-18-fluoro-L-DOPA in PET of pheochromocytorna and extraadrenal abdominal paraganglioma. J Nucl Med 2007; 48: 1599-1606. (Pubitemid 47572706)
71. Fiebrich HB, Brouwers AH, Kerstens MN, et al.: 6- F-18 fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with I-123-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess. J Clin Endocrinol Metab 2009; 94: 3922-3930.
72. Rufini V, Treglia G, Castaldi P, et al.: Comparison of (123)I-MIBG SPECT-CT and (18)F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun 2011; 32: 575-582.
73. Taieb D, Tessonnier L, Sebag F, et al.: The role of F-18-FDOPA and F-18-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol 2008; 69: 580-586.
74. Krausz Y, Freedman N, Rubinstein R, et al.: (68)Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: Comparison with (111)In-DTPA-Octreotide (OctreoScan (R)). Mol Imaging Biol 2011; 13: 583-593.
75. Naji M, Zhao CL, Welsh SJ, et al.: (68)Ga-DOTA-TATE PET vs. (123)I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol 2011; 13: 769-775.
76. Grovas A, Fremgen A, Rauck A, et al.: The national cancer data base report on patterns of childhood cancers in the United States. Cancer 1997; 80: 2321-2332. (Pubitemid 28007404)
77. Navalkele P, O'Dorisio MS, O'Dorisio TM, et al.: Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: Nine standard SEER registries, 1975-2006. Pediatr Blood Cancer 2011; 56: 50-57.
78. Cohn SL, Pearson ADJ, London WB, et al.: The international neuroblastoma risk group (INRG) classification System: An INRG task force report. J Clin Oncol 2009; 27: 289-297.
79. Brisse HJ, McCarville MB, Granata C, et al.: Guidelines for imaging and staging of neuroblastic tumors: Consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011; 261: 243-257.
80. Feine U, Mullerschauenburg W, Treuner J, et al.: Metaiodobenzylguanidine (metaiodobenzylguanidine) labeled with I-123/I-131 in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the international workshop of pediatric oncology held in rome, september 1986. Med Pediatr Oncol 1987; 15: 181-187. (Pubitemid 18025974)
81. Abrahamsen J, Lyck B, Helgestad J, et al.: The impact of I-123 metaiodobenzylguanidine scintigraphy on diagnostics and follow-up of neuroblastoma. Acta Oncol 1995; 34: 505-510.
82. Rufini V, Fisher GA, Shulkin BL, et al.: Iodine-123-MIBG imaging of neuroblastoma: Utility of SPECT and delayed imaging. J Nucl Med 1996; 37: 1464-1468. (Pubitemid 26321623)
83. Vik TA, Pfluger T, Kadota R, et al.: (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer 2009; 52: 784-790.
84. Kushner BH, Yeh SDJ, Kramer K, et al.: Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003; 21: 1082-1086. (Pubitemid 46594137)
85. Troncone L, Rufini V, Danza FM, et al.: Radioiodinated metaiodobenzylguanidine (I-metaiodobenzylguanidine) scintigraphy in neuroblastoma-a review of 160 studies. J Nucl Med Allied Sci 1990; 34: 279-288.
86. Osmanagaoglu K, Lippens M, Benoit Y, et al.: A comparison of I-123 metaiodobenzylguanidine scintigraphy and single bone-marrow aspiration biopsy in the diagnosis and follow-up of 26 children with neuroblastoma. Eur J Nucl Med 1993; 20: 1154-1160. (Pubitemid 24035318)
87. Gordon I, Peters AM, Gutman A, et al.: Skeletal assessment in neuroblastoma-the pitfalls of iodine-123-mIBG scans. J Nucl Med 1990; 31: 129-134. (Pubitemid 20059210)
88. Sautterbihl ML, Bihl H, Heinze HG:, The value of TC-99M-MDP bone- scintigraphy in patients with neuroblastoma. Nuklearmedizin 1991; 30: 7-12.
89. Albers AR, O'Dorisio MS, Balster DA, et al.: Somatostatin receptor gene expression in neuroblastoma. Regul Pept 2000; 88: 61-73. (Pubitemid 30114387)
90. Briganti V, Sestini R, Orlando C, et al.: Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res 1997; 3: 2385-2391. (Pubitemid 28133159)
91. Schilling FH, Bihl H, Jacobsson H, et al.: Combined In-111-pentetreotide scintigraphy and I-123-mIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol 2000; 35: 688-691.
92. Moertel CL, Reubi JC, Scheithauer BS, et al.: Expression of somatostatin receptors in childhood neuroblastoma. Am J Clin Pathol 1994; 102: 752-756.
93. Kropp J, Hofmann M, Bihl H:, Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor ? Anticancer Res 1997; 17: 1583-1588. (Pubitemid 27263126)
94. Raggi CC, Maggi M, Renzi D, et al.: Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome. J Clin Endocrinol Metab 2000; 85: 3866-3873.
95. Kroiss A, Putzer D, Uprimny C, et al.: Functional imaging in phaeochromocytoma and neuroblastoma with (68)Ga-DOTA-Tyr(3)-octreotide positron emission tomography and (123)I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging 2011; 38: 865-873.
96. Brans B, Laureys G, Schelfhout V, et al.: Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: Lack of relation to tumour differentiation in vivo. Eur J Nucl Med 1998; 25: 144-149. (Pubitemid 28130038)
97. Shulkin BL, Hutchinson RJ, Castle VP, et al.: Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996; 199: 743-750.
98. Sharp SE, Shulkin BL, Gelfand MJ, et al.: (123)I-MIBG scintigraphy and (18)F-FDG PET in neuroblastoma. J Nucl Med 2009; 50: 1237-1243.
99. Papathanasiou ND, Gaze MN, Sullivan K, et al.: (18)F-FDG PET/CT and (123)I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: Diagnostic comparison and survival analysis. J Nucl Med 2011; 52: 519-525.
100. Melzer HI, Coppenrath E, Schmid I, et al.: (123)I-MIBG scintigraphy/SPECT versus (18)F-FDG PET in paediatric neuroblastoma. Eur J Nucl Med Mol Imaging 2011; 38: 1648-1658.
101. Kushner BH, Yeung HWD, Larson SM, et al.: Extending positron emission tomography scan utility to high-risk neuroblastoma: Fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol 2001; 19: 3397-3405. (Pubitemid 32642193)
102. Colavolpe C, Guedj E, Cammilleri S, et al.: Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer 2008; 51: 828-831.
103. Taggart DR, Han MM, Quach A, et al.: Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and (18)F fluorodeoxyglucose positron emission tomography to Evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009; 27: 5343-5349.
104. Kushner BH, Kramer K, Modak S, et al.: Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol 2009; 27: 1041-1046.
105. Piccardo A, Lopci E, Conte M, et al.: Comparison of (18)F-dopa PET/CT and (123)I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: A pilot study. Eur J Nucl Med Mol Imaging 2012; 39: 57-71.
106. Shulkin BL, Wieland DM, Baro ME, et al.: PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 1996; 37: 16-21. (Pubitemid 26125958)
107. Pacak K, Eisenhofer G, Carrasquillo JA, et al.: Diagnostic localization of pheochromocytoma-The coming of age of positron emission tomography. In:, Pacak K, Eisenhofer G, Editors: " Ann Ny Acad Sci.". 2002; 970: 170-176. (Pubitemid 35286094)
108. Matthay KK, Shulkin B, Ladenstein R, et al.: Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: A report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010; 102: 1319-1326.
109. Vikram R, Yeung HDW, Macapinlac HA, et al.: Utility of PET/CT in differentiating benign from malignant adrenal nodules in patients with cancer. Am J Roentgenol 2008; 191: 1545-1551.
110. Miskulin J, Shulkin BL, Doherty GM, et al.: Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma ? Surgery 2003; 134: 918-922.
111. Lumachi F, Tregnaghi A, Zucchetta P, et al.: Sensitivity and positive predictive value of CT, MRI and I-123-MIBG scintigraphy in localizing pheochromocytomas: A prospective study. Nucl Med Commun 2006; 27: 583-587. (Pubitemid 44305314)
112. van der Harst E, de Herder WW, Bruining HA, et al.: [I-123] metaiodobenzylguanidine and [In-111]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001; 86: 685-693. (Pubitemid 32207482)
113. Luster M, Karges W, Zeich K, et al.: Clinical value of F-18-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (F-18-DOPA PET/CT) for detecting pheochromocytoma. Eur J Nucl Med Mol Imaging 2010; 37: 484-493.
114. Shapiro B, Copp JE, Sisson JC, et al.: I-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma-experience in 400 cases. J Nucl Med 1985; 26: 576-585. (Pubitemid 16033416)
115. Taieb D, Tessonnier L, Mundler O:, Positron emission tomography in digestive neuroendocrine tumors: Choice of the tracer. Medecine Nucleaire-Imagerie Fonctionnelle Et Metabolique 2009; 33: 712-717.
116. ShalabyRana E, Majd M, Andrich MP, et al.: In-111 pentetreotide scintigraphy in patients with neuroblastoma-Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome. Clin Nucl Med 1997; 22: 315-319. (Pubitemid 27203424)